Market research
FATE Fate Therapeutics Inc
NASDAQ USD Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 260M
- P/E ratio
- Not available
- Analyst target
- 5.7444
- Dividend yield
- Not available
- Beta
- 2.53
Profile
Instrument facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 260M
- P/E ratio
- Not available
- Analyst target
- 5.7444
- Dividend yield
- Not available
- Beta
- 2.53
About
About Fate Therapeutics Inc
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex autoimmune diseases; and FT825 to treat solid tumors. It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. The company was incorporated in 2007 and is headquartered in San Diego, California.
Research context
Fate Therapeutics Inc appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the FATE discussion.
5 years, 6 months ago
Fate Therapeutics, Inc is currently in a long term uptrend where the price is trading 8.9% above its 200 day moving average.
From a valuation standpoint, the stock is 83.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 219.3.
Fate Therapeutics, Inc's total revenue rose by 467.3% to $16M since the same quarter in the previous year.
Its net income has dropped by 87.7% to $-53M since the same quarter in the previous year.
Finally, its free cash flow grew by 18.4% to $-23M since the same quarter in the previous year.
Based on the above factors, Fate Therapeutics, Inc gets an overall score of 4/5.